Literature DB >> 8595252

Increased plasma alpha (1 --> 3)-L-fucosyltransferase activities in patients with hepatocellular carcinoma.

T Hada1, K Fukui, M Ohno, S Akamatsu, S Yazawa, K Enomoto, K Yamaguchi, Y Matsuda, Y Amuro, N Yamanaka.   

Abstract

Alpha (1 --> 3)-L-fucosyltransferase (alpha 1,3FT) activity was determined in plasma of patients with chronic liver diseases, namely, chronic hepatitis (CH), liver cirrhosis (LC) and hepatocellular carcinoma (HCC), The plasma alpha 1,3FT activity was significantly higher (p < 0.01) in chronic liver diseases than that in normal controls. The enzyme activity in plasma of patients with HCC was also significantly higher than that in LC (p < 0.05) or that in CH (p < 0.01). However, no significant difference was observed in the enzyme activity between LC and CH. Plasma alpha 1,3FT activity in patients with HCC was not significantly changed before and after transcatheter arterial embolization. In addition, the enzyme activity in the homogenate of the cirrhotic liver tissue was higher than that in the preparation of the hepatoma tissue in the same patient. These results suggest that the increased plasma alpha 1,3FT activity in patients with HCC reflects mainly the enzyme activity of cirrhotic liver tissue, not that of hepatoma tissue. The significance of the elevated levels of plasma alpha 1,3FT and its decreased hepatoma tissue activity in patients with HCC, compared with that in LC, remains to be clarified.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8595252     DOI: 10.1007/bf00731257

Source DB:  PubMed          Journal:  Glycoconj J        ISSN: 0282-0080            Impact factor:   2.916


  19 in total

Review 1.  Alpha-fetoprotein: reevaluation in hepatology.

Authors:  K Taketa
Journal:  Hepatology       Date:  1990-12       Impact factor: 17.425

2.  Comparative study of the sugar chains of gamma-glutamyltranspeptidases purified from human hepatocellular carcinoma and from human liver.

Authors:  K Yamashita; K Totani; Y Iwaki; I Takamisawa; N Tateishi; T Higashi; Y Sakamoto; A Kobata
Journal:  J Biochem       Date:  1989-05       Impact factor: 3.387

3.  Novel cholinesterase expression in the HuH-7 cell line.

Authors:  T Hada; T Yamamoto; H Imanishi; S Takahashi; Y Amuro; K Higashino; J Sato
Journal:  Tumour Biol       Date:  1987

4.  Altered glycosylation of serum transferrin of patients with hepatocellular carcinoma.

Authors:  K Yamashita; N Koide; T Endo; Y Iwaki; A Kobata
Journal:  J Biol Chem       Date:  1989-02-15       Impact factor: 5.157

5.  Discrimination of liver cirrhosis from chronic hepatitis by analysis of serum cholinesterase isozymes using affinity electrophoresis with concanavalin A or wheat germ agglutinin.

Authors:  T Hada; T Ohue; H Imanishi; H Nakaoka; A Hirosaki; S Shimomura; M Fujikura; Y Matsuda; T Yamamoto; Y Amuro
Journal:  Gastroenterol Jpn       Date:  1990-12

6.  Evaluation of the degree of desialylation of serum C1-inactivator and haemopexin.

Authors:  N S Serbource-Goguel Seta; M C Bordas; J M Féger; J A Davy; G M Durand
Journal:  Clin Chim Acta       Date:  1984-11-30       Impact factor: 3.786

7.  Ovarian cancer alpha 1,3-L-fucosyltransferase. Differentiation of distinct catalytic species with the unique substrate, 3'-sulfo-N-acetyllactosamine in conjunction with other synthetic acceptors.

Authors:  E V Chandrasekaran; R K Jain; K L Matta
Journal:  J Biol Chem       Date:  1992-11-25       Impact factor: 5.157

8.  Fractionation of L-fucose-containing oligosaccharides on immobilized Aleuria aurantia lectin.

Authors:  K Yamashita; N Kochibe; T Ohkura; I Ueda; A Kobata
Journal:  J Biol Chem       Date:  1985-04-25       Impact factor: 5.157

9.  Increase of fucosylated serum cholinesterase in relation to high risk groups for hepatocellular carcinomas.

Authors:  T Ohkura; T Hada; K Higashino; T Ohue; N Kochibe; N Koide; K Yamashita
Journal:  Cancer Res       Date:  1994-01-01       Impact factor: 12.701

10.  Cancer-associated elevation of alpha(1----3)-L-fucosyltransferase activity in human serum.

Authors:  S Yazawa; R Madiyalakan; H Izawa; T Asao; K Furukawa; K L Matta
Journal:  Cancer       Date:  1988-08-01       Impact factor: 6.860

View more
  5 in total

1.  Tumor cells as the origin of elevated serum alpha1,3fucosyltransferase in association with malignancy.

Authors:  T Asao; H Kuwano; J Nakamura; A Okamura; E G Berger; K L Matta; S Yazawa
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  A novel method for determination of alpha1,6fucosyltransferase activity using a reducing oligosaccharide from egg yolk as a specific acceptor.

Authors:  S Yazawa; N Kochibe; T Nishimura; C Shima; I Takai; M Adachi; T Asao; T Hada; Y Enoki; L R Juneja
Journal:  Glycoconj J       Date:  1998-09       Impact factor: 2.916

3.  The usefulness of anti-fucosylated antigen antibody YB-2 for diagnosis of hepatocellular carcinoma.

Authors:  J Nakamura; S Yazawa; T Hada; T Asao; H Naitoh; S Takenoshita; M Kosaka; S Akamatsu; T Tachikawa; Y Nagamachi
Journal:  Glycoconj J       Date:  1997-01       Impact factor: 2.916

4.  A high throughput method for identifying personalized tumor-associated antigens.

Authors:  Yurij Ionov
Journal:  Oncotarget       Date:  2010-06

5.  Fucosylated Glycans in α1-Acid Glycoprotein for Monitoring Treatment Outcomes and Prognosis of Cancer Patients.

Authors:  Shin Yazawa; Ryo Takahashi; Takehiko Yokobori; Rie Sano; Akira Mogi; Abby R Saniabadi; Hiroyuki Kuwano; Takayuki Asao
Journal:  PLoS One       Date:  2016-06-13       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.